Skip to main content
padlock icon - secure page this page is secure

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies

Buy Article:

$52.00 + tax (Refund Policy)

To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 100% response; CGRP; galcanezumab; migraine; prevention

Document Type: Research Article

Publication date: October 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more